In March 2025, the company declared new plans for a direct-to-consumer featuring of its Wegovy weight loss drug. The company established a different pharmacy, termed NovoCare, which would charge clients $499 every month for access to the drug, a lot less than 50 percent the cost of the drug by means of other pharmaceutical distribution networks.[53